The Frequency Fix: A Sticker Promising Wellness Enters the US Market

FORT LAUDERDALE, Fla. – July 17, 2026 – In a wellness market saturated with supplements, smartwatches, and stringent diets, a new contender from Spain is betting on a different approach: a small, wearable disc that promises to support well-being not by adding something to the body, but by communicating with it.

ANF Care™, the consumer brand of Marbella-based Amino Frequency Corporation S.L., is launching its technology in the United States this year. The product is a collection of discreet, adhesive discs, described as being “frequency-coded.” Applied directly to the skin, they contain no drugs, require no batteries, and are intended to work non-invasively, supporting what the company calls “BioCoherence”—the body’s natural rhythms and patterns.

The concept challenges the dominant paradigm of wellness, which often involves ingestion or intervention. It’s a vision articulated by the technology's creator, Dr. Mikel Hoff, founder of the associated ANF Academy.

"Who said you need a routine of pills and supplements to feel your best?" Dr. Hoff stated in the company's announcement. "Our technology offers a natural, non-invasive way to support everyday wellness. It's a simple wearable — like your smart watch — with no medications and nothing to ingest."

For a US consumer base accustomed to tracking every metric and popping a vitamin for every ailment, the idea of a passive sticker that tunes the body’s own frequencies sounds either revolutionary or radically far-fetched. As ANF Care™ prepares to carve out its niche, the central question is whether this technology represents a new frontier in personal health or simply the latest chapter in the long history of wellness marketing.

Unpacking the Science of Frequencies

The foundation of ANF Care’s technology rests on the principles of “neurobiofrequency.” The idea is that our bodies, down to the cellular level, operate on specific frequencies. When these frequencies are disrupted by stress, injury, or inflammation, our sense of well-being suffers. The ANF discs, activated by body heat, are said to emit frequencies that help restore the body's natural state of balance, or BioCoherence.

This isn't entirely without precedent. The scientific community acknowledges that cells and organs possess resonant frequencies. Preliminary research has even explored the effects of external frequencies, like the Earth’s natural Schumann Resonance (around 7.83 Hz), on human brainwaves and stress levels. However, the field of “bioresonance therapy,” to which this technology is related, occupies a contentious space.

Major medical institutions and regulatory bodies have long held that while the theories are intriguing, they remain largely unproven. The American Cancer Society, for instance, has cautioned against using unproven electronic devices for treatment, citing a lack of sound scientific evidence. The primary critique is the scarcity of large-scale, double-blind, placebo-controlled studies—the gold standard of medical research—to validate the claims made by many frequency-based therapies.

ANF Academy, the educational arm behind the technology, has begun to build its own body of evidence. A multi-site observational study published by the academy, involving over 1,000 patients, reported significant pain reduction and high patient satisfaction. Yet, the study's authors correctly note that this provides “preliminary evidence” and recommend future research include a sham or placebo intervention to establish efficacy more conclusively. For the discerning consumer, the line between established science and proprietary research can be difficult to navigate.

A Murky Regulatory Path

Adding to the complexity is the product's regulatory positioning. According to company literature, ANF devices are registered as Class I medical devices with the FDA, a classification that applies to low-risk products like elastic bandages and tongue depressors. This registration primarily denotes adherence to safety standards and proper labeling, rather than an endorsement of efficacy.

Simultaneously, the ANF Care™ consumer website features a familiar disclaimer: “These statements have not been evaluated by the FDA. They are not a medical device and are not designed to treat, cure, or diagnose any condition.” This dual messaging creates a fog of confusion. Is it a low-risk medical device or a general wellness product with no medical claims? The distinction is critical. General wellness products can make claims about supporting sleep or reducing stress, but they cannot claim to treat pain or inflammation, areas where the company’s practitioner-focused therapy, ANF Therapy®, has centered its research.

This careful tightrope walk is common in the wellness industry, but it places the burden of discernment squarely on the consumer. Are they buying a product with a baseline of regulatory oversight, or a lifestyle accessory whose benefits are subjective? For a brand entering the litigious and highly competitive US market, clarity will be paramount.

From Practitioners to the People

While new to the American consumer, the technology behind ANF Care™ is not without a history. It is the result of 15 years of research and development by Dr. Hoff, and its professional-grade application, ANF Therapy®, has been adopted by a reported 1,500 practitioners in over 50 countries. This existing network of physiotherapists, osteopaths, and physicians lends the brand a degree of credibility that most wellness startups lack.

Practitioners who have integrated the therapy into their work report positive outcomes, particularly for patients with chronic pain and inflammation. One therapist noted that the discs provide a way to “continue the work” between sessions, helping to address the root cause of inflammation rather than just masking symptoms. Patient testimonials often describe subtle but steady improvements. One user described the effect as a “quieter mind before sleep and less scattered mornings,” emphasizing the changes are gradual, not a dramatic overnight fix.

However, the company’s own research notes that mild, short-term side effects like headaches, fatigue, and dry mouth occurred in a notable percentage of patients, which it attributes to the body's detoxification or normalization process. As ANF Care™ transitions from a practitioner-guided tool to a direct-to-consumer product, it will face the challenge of managing user expectations and providing clear guidance for a public accustomed to immediate results and simple instructions. The ultimate test for this intriguing technology will not be in a lab or a clinic, but in the day-to-day lives of American consumers, who will decide for themselves whether a small, silent disc holds the frequency of a healthier life.